CBD Oil Color Testing: Strong Calibration Does Not Eliminate Full-Spectrum Matrix Error
A low-cost color reaction can quantify CBD under specified laboratory conditions, but excellent calibration does not guarantee equally accurate results for every cannabis oil. In a Beam-reaction study, the full-spectrum product produced a higher estimate than the chromatographic comparison.
What the method was designed to do
The researchers developed a UV–visible spectrophotometric method for medicinal oils. CBD reacts under alkaline conditions to produce a violet product measured at 530 nanometers. The optimized procedure used a 24-hour incubation to obtain a stable signal.
This was analytical research on standards, fortified matrices and commercial oils. It did not measure cannabinoids in human blood, saliva or urine, and it did not test intoxication. A concentration range validated in an oil-assay workflow cannot simply be applied to biological specimens.
The two commercial oils tell an important story
Calibration was highly linear over 50–250 micrograms per milliliter. Nevertheless, the two real products did not perform identically. For the purified-CBD oil, the chromatographic comparison was 65.9 mg/mL and the colorimetric estimate was 64.67 mg/mL. For the full-spectrum oil, the corresponding estimates were 30 and 37.37 mg/mL.
The latter is an approximately 24.6% higher central estimate. The authors describe greater dispersion and possible contributions from co-extracted compounds. Those observations should accompany any claim that the inexpensive method performed comparably with chromatography.
Recovery and selectivity answer different questions
High recovery in a spiking experiment means that added analyte was recovered effectively under those conditions. It does not show that every component contributing to a color signal is the intended analyte. A separation method and a bulk color reaction offer different protections against interference.
The reported quantification limit of 5.58 micrograms per milliliter also belongs to this assay. It is not a universal CBD detection limit, a product-compliance threshold or a concentration associated with a clinical effect.
How to assess a disputed product result
Identify whether the tested material was an isolate formulation or a complex extract, how it was diluted and extracted, and whether the method was validated for that formulation. Request uncertainty estimates, matrix-matched quality controls and a suitable independent comparison when a small concentration difference matters.
The study supports accessible quality-control testing, especially for purified formulations. Its limited commercial-product comparison does not establish universal accuracy across oils, creams and all full-spectrum cannabis products, and it cannot substitute for evidence about a person’s exposure or impairment.
Related analysis: Equal THC Doses, Different Plasma Profiles: A Human Formulation Trial.
Primary research
Fresia Melina Silva Sofras and colleagues. Development and validation of a low-cost spectrophotometric method for cannabidiol (CBD) quantification based on the Beam reaction. Journal of Cannabis Research (2026). DOI: 10.1186/s42238-026-00473-1.
